YTHDF2 and central nervous system cancer: While YTHDF1 and YTHDF2 mutations only occur in 0.9 and 0.5% of glioma cases respectively [13], several published datasets, including from The Cancer Genome Atlas (TCGA), show that YTHDF1 and YTHDF2 mRNA expression levels are positively correlated with malignancy of gliomas, with significant increases in higher grade gliomas, suggesting a role for these m6A readers in glioma progression [13, 15, 112].